Alvotech Holdings S.A Logo

Alvotech Holdings S.A

Develops and manufactures affordable biosimilar medicines for global patient access.

ALVO | LU

Overview

Corporate Details

ISIN(s):
LU2458332611
LEI:
222100DCZBOWV5DZ8372
Country:
Luxembourg
Address:
9, RUE DE BITBOURG, L-1273 LUXEMBOURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alvotech is a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines. The company's mission is to improve lives by increasing patient access to high-quality, affordable biologic treatments worldwide. Alvotech operates a vertically integrated platform, managing the entire process from cell line development to fill-and-finish manufacturing. This end-to-end approach provides control, scale, and speed in its development and production processes. For global commercialization, the company forms strategic partnerships with third parties to market and distribute its robust pipeline of biosimilars to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-24 11:30
Regulatory Filings
Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech v…
Icelandic 8.4 KB
2025-11-24 11:30
Regulatory Filings
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denos…
English 13.3 KB
2025-11-20 10:00
Regulatory Filings
Alvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobi…
Icelandic 7.4 KB
2025-11-20 10:00
Regulatory Filings
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Econo…
English 13.7 KB
2025-11-12 22:40
Earnings Release
Alvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstr…
Icelandic 24.6 KB
2025-11-12 22:40
Earnings Release
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Busin…
English 29.2 KB
2025-11-10 10:00
Legal Proceedings Report
Alvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AV…
Icelandic 7.9 KB
2025-11-10 10:00
Legal Proceedings Report
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market …
English 10.3 KB
2025-11-06 15:00
Regulatory Filings
Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu …
Icelandic 7.2 KB
2025-11-06 15:00
Regulatory Filings
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Bio…
English 16.4 KB
2025-11-04 22:01
Report Publication Announcement
Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekst…
Icelandic 3.7 KB
2025-11-04 22:01
Report Publication Announcement
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for…
English 5.9 KB
2025-11-02 23:10
Legal Proceedings Report
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05…
Icelandic 6.4 KB
2025-11-02 23:10
Regulatory Filings
Alvotech Provides Update on the Status of U.S. Biologics License Application fo…
English 7.6 KB
2025-10-22 11:00
Board/Management Information
Skipulagsbreytingar á viðskiptasviði Alvotech
Icelandic 6.6 KB

Automate Your Workflow. Get a real-time feed of all Alvotech Holdings S.A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alvotech Holdings S.A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alvotech Holdings S.A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.